Results 171 to 180 of about 110,217 (215)
The 340B Program: A Federal Program in Desperate Need of Revision After Two-And-A-Half Decades of Uncertainty [PDF]
, 2019 Fisher, Nicholas C.
core +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Abstract Orphan drug designation for the EU, UK, and USA is described, highlighting the requirements and potential incentives on offer for development of medicines for patients with rare diseases.
Phil Ambery +2 more
+4 more sources
Phil Ambery +2 more
+4 more sources
Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti, 2001
The paper discusses the problems of orphan drugs from the standpoint of the attitude of state authorities in the USA, Japan, and particularly Europe (the European Union) to their definition and the formation of appropriate legislation--financial provision for the development, production, provision of exclusive sale rights--which warranties the ...
J, Kolár, M, Chalabala, H, Srámková
openaire +1 more source
The paper discusses the problems of orphan drugs from the standpoint of the attitude of state authorities in the USA, Japan, and particularly Europe (the European Union) to their definition and the formation of appropriate legislation--financial provision for the development, production, provision of exclusive sale rights--which warranties the ...
J, Kolár, M, Chalabala, H, Srámková
openaire +1 more source
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Ca-A Cancer Journal for Clinicians, 2022Paolo Tarantino +2 more
exaly